Current Drug Safety


Seetal Dodd
School of Medicine
University of Melbourne
Geelong, Melbourne

Personal Subscription
Become EABM
Become Reviewer
Call for Editor

Managing Safety Signals in Large Endpoint Trials

Volume:3   Issue: 2
Pp: 86-90
Demissie Alemayehu
DOI: 10.2174/157488608784529206

Advances in Machine Learning Prediction of Toxicological Properties and Adverse Drug Reactions of Pharmaceutical Agents

Volume:3   Issue: 2
Pp: 100-114
Xiao Hua Ma, Rong Wang, Yin Xue, Ze Rong Li, Sheng Yong Yang, Yu Quan Wei and Yu Zong Chen
DOI: 10.2174/157488608784529224

Side Effects of Clozapine and Some Other Psychoactive Drugs

Volume:3   Issue: 2
Pp: 115-122
Robert J. Flanagan
DOI: 10.2174/157488608784529251

The Effect of Pharmacotherapy for Attention Deficit Hyperactivity Disorder on Risk of Seizures in Pediatric Patients as Assessed in an Insurance Claims Database

Volume:3   Issue: 2
Pp: 123-131
Andrew T. McAfee, Karen C. Holdridge, Catherine B. Johannes, Kenneth Hornbuckle and Alexander M. Walker
DOI: 10.2174/157488608784529233

Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data

Volume:3   Issue: 2
Pp: 132-142
Joachim Wernicke, Beth Pangallo, Fujun Wang, Isabelle Murray, Judith W. Henck, Mary Pat Knadler, Deborah N. D'Souza and Jack P. Uetrecht
DOI: 10.2174/157488608784529189

Hepatic Effects of Duloxetine-II: Spontaneous Reports and Epidemiology of Hepatic Events

Volume:3   Issue: 2
Pp: 143-153
Joachim Wernicke, Nayan Acharya, Indiana Strombom, James L. Gahimer, Deborah N. D'Souza, Natalie DiPietro and Jack P. Uetrecht
DOI: 10.2174/157488608784529198

Hepatic Effects of Duloxetine – III: Analysis of Hepatic Events Using External Data Sources

Volume:3   Issue: 2
Pp: 154-162
Indiana Strombom, Joachim F. Wernicke, John Seeger, Deborah N. D'Souza and Nayan Acharya
DOI: 10.2174/157488608784529215